查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1776211

血栓管理設備的全球市場:洞察，競爭情形，市場預測:2032年

Clot Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2024年，血栓管理設備市場規模達18.3879億美元。預計2025年至2032年期間，該市場規模將以4.63%的複合年增長率成長，到2032年將達到26.3273億美元。心血管疾病、糖尿病和高血壓等生活方式相關疾病的盛行率不斷上升，以及持續的產品創新，正在推動血栓管理設備市場的成長。心血管疾病及其相關風險正在推動對先進血栓預防和治療技術的需求。此外，微創高效設備（例如機械血栓切除工具和導管系統）的新技術發展，正在推動市場發展，並使醫護人員更輕鬆地管理血栓疾病。預計這些綜合因素將在2025年至2032年的預測期內推動血栓管理設備市場整體擴張。

血栓管理設備市場動態：

根據英國心臟基金會提供的最新數據（2024年），全球約有6.2億人（約佔全球人口的1/13），患有心臟和循環系統疾病。此外，根據英國心臟基金會提供的最新數據（2024年），冠狀動脈（缺血性）心臟病影響全球約2億人，其中包括約1.1億名男性和8,000萬名女性。此外，約有5600萬女性和4500萬男性是卒中倖存者。據估計，全球至少有1,300萬人患有先天性心臟病，另有數百萬人可能未被診斷。

心血管疾病（CVD），包括心臟病發作、中風和周邊動脈疾病，發病率的不斷上升，大大推動了血栓管理設備市場的發展。這些疾病通常伴隨血栓形成，如果不及時治療，可能導致危及生命的併發症。血栓管理設備，包括機械血栓切除系統和導管介入血栓溶解術，為去除或溶解血栓提供了微創選擇，改善了患者的預後，並減少了對複雜手術的需求，從而推動了全球市場的成長。

此外，根據國際糖尿病聯盟 (IDF) 最新數據，2021 年約有 5.37 億 20 至 79 歲的成年人患有糖尿病。預計到 2030 年，這一數字將增至 6.43 億，到 2045 年將增至 7.83 億。

此外，根據 IDF 糖尿病地圖集提供的最新數據，2022 年全球 875 萬第 1 型糖尿病患者中，有 152 萬人未滿 20 歲。此外，2022 年新發生 1 型糖尿病患者中 62% 年齡在 20 歲或以上。糖尿病盛行率的上升推動了對血栓管理設備的需求，因為糖尿病會顯著增加血管併發症（包括血栓形成）的風險。這種風險的增加需要先進的血栓管理解決方案，例如血栓切除裝置、導管介導的血栓溶解術以及其他旨在快速溶解或清除血栓、改善血流並減少併發症的微創手術，從而促進全球血栓管理設備市場的整體成長。

此外，各公司正透過擴大血栓管理設備的生產規模和獲得新產品的批准，策略性地擴大其市場佔有率，從而推動進一步的成長。例如，2025年3月，Imperative Care, Inc.宣布其82公分Symphony™ 16F導管已獲得美國食品藥物管理局(FDA) 510(k)批准。該導管是該公司最新的創新產品，旨在改善靜脈血栓形成患者的照護。靜脈血栓形成是一種由腿部和腹部靜脈中形成的血栓引起的嚴重且危及生命的疾病。

然而，產品召回事件的增加以及血栓管理器械相關併發症的風險，例如出血、血管損傷和感染，可能會阻礙血栓管理器械市場的未來發展。

血栓管理器械市場區隔分析：

按產品類型劃分的血栓管理市場中，支架取栓器預計將在2024年佔據最大佔有率。這可能是由於使用支架取栓器進行機械血栓切除術的優勢，據報道，與單純藥物治療相比，支架取栓器在急性中風患者中可帶來更佳的臨床療效。此外，支架取栓器的安全性與全身性溶栓療法相似。這些器械旨在以機械方式從腦部阻塞的動脈中清除血栓，從而在關鍵時間內快速有效地恢復血流，防止長期神經損傷。

此外，產品設計的改進，例如加入鉑金以提高可見度（Trevo Provue 和 Solitaire Platinum）以及將長度延長至 40 毫米，有助於改善首次再灌注結果。可回收自膨脹式血栓切除裝置的出現提供了更多優勢，例如可立即恢復血流，無需放置永久性支架，從而降低支架內再狹窄的可能性。與單純的傳統溶栓療法相比，支架回收器可提供更佳的療效，包括更高的血管再通率、更好的功能恢復和更低的死亡率。這使得它們被納入主要的卒中治療指南，並在世界各地的醫院和卒中中心加速推廣。此外，技術創新，例如具有增強徑向力、改善血栓完整性和改進導航的下一代支架回收器，正在進一步擴展支架回收器的臨床應用。

此外，新產品的推出可能會在預測期內推動全球支架取栓器市場蓬勃發展。例如，2024年8月，Gravity Medical Technology宣布推出其下一代中風治療設備－中子抽吸導管和Supernova支架取栓器。 Supernova支架取栓器的創新設計增強了對富含纖維蛋白的硬性（白色）血塊的捕獲和清除能力，而這類血塊在非白種人群中更為常見。

因此，基於上述因素，預計在預測期內，支架取栓器類別將創造可觀的收入，並推動全球血栓管理設備市場的整體成長。

預計到2024年，北美將在血栓管理設備市場中佔據所有地區中的最高佔有率。由於肥胖、高血壓和糖尿病盛行率上升，深部靜脈栓塞 (DVT) 和栓塞盛行率上升，人口老化，癌症盛行率上升以及政府在疾病治療意識方面的舉措不斷增多，預計北美血栓管理設備市場在預測期內將出現正增長。

根據美國疾病管制與預防中心 (CDC) 2024 年的最新數據，2022 年約有 4.9% 的成年人被診斷出患有冠心病。此外，預計到 2023 年，美國將有 1,210 萬人罹患心房顫動。此外，美國每年有超過 79.5 萬人罹患中風，其中約 61 萬人是首次中風。值得注意的是，其中近18.5萬例中風患者（約佔四分之一）曾經中風。

冠狀動脈心臟病 (CHD) 盛行率的上升極大地推動了血栓管理設備市場的發展。由於血栓通常在冠狀動脈中形成，因此對恢復血流和預防心臟病發作的有效治療的需求日益增長。血栓切除設備和栓塞系統等血栓管理設備對於管理這種疾病至關重要，並正在推動其在醫院和急診室的應用。

此外，根據美國疾病管制與預防中心 (CDC) 提供的最新報告（2024 年），估計各年齡層將有 3,840 萬人（占美國人口的 11.6%）患有糖尿病。此外，18 歲及以上人口中約有 3,810 萬人患有糖尿病，占美國成年人口的 14.7%。糖尿病常導致周邊動脈疾病和深部靜脈血栓等併發症，這些併發症會導致血栓阻塞血管，阻礙血液循環。糖尿病患者對有效血栓預防和治療的需求日益增長，這推動了血栓管理設備（包括血栓切除術和導管系統）在醫院和門診的普及，擴大了該地區的市場。

此外，美國人口癌症盛行率的上升也是積極影響美國血栓管理設備市場成長的關鍵因素之一。根據 GLOBOCAN 提供的最新數據，2022 年北美新增癌症病例估計為 267 萬例，預計到 2045 年將增加至 383 萬例。癌症患者被認為存在某些異常的凝血因子，這會增加血栓形成的可能性。此外，化療也會增加靜脈血栓的風險，導致深部靜脈血栓形成。因此，預計美國癌症盛行率的上升將推動血栓管理設備需求的成長，增加產品需求，並支持北美血栓管理設備市場的成長。

此外，主要市場參與者的策略活動增加，可能會在預測期內迅速推動該地區血栓管理設備市場的發展。例如，2023年6月，全球醫療保健公司Penumbra, Inc.獲得FDA批准，並推出了先進的動脈血栓清除系統Lightning Bolt™ 7。本設備結合Lightning智慧抽吸技術與微處理器演算法，實現了可調節的吸力。該設備旨在快速清除較大的纖維性動脈血栓，同時最大限度地減少出血，適用於急性肢體缺血(ALI)、休眠血栓和內臟阻塞等病症。

因此，預計上述因素將在預測期內推動北美血栓管理設備市場的成長。

血栓管理設備市場的主要參與者

血栓管理設備市場的主要參與者包括愛德華生命科學公司 (Edward LifeSciences Corporation)、史賽克 (Stryker)、醫療器材業務服務公司 (Medical Device Business Services, Inc.)、美敦力公司 (Medtronic PLC)、Penumbra、Microvention 公司、泰爾茂公司 (Terumo Corporation、波士頓科學公司 (Yusston Sci)、Yuscan媽媽、Hashcan、Hflowa)、波士頓科學公司 (Cston00)、Hillas G Ltd.、荷蘭皇家飛利浦公司 (Koninklijke Philips N.V.)、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、康德樂 (Cardinal Health)、Braille Biomedica 和庫克 (Cook)。

血栓管理設備市場的最新發展：

  • 2024年4月，Penumbra Inc. 推出了 Lightning Flash 2.0——用於快速清除血栓的最新 CAVT 技術。
  • 2024年2月，強生醫療科技公司 CERENOVUS, Inc. 宣布推出 CEREGLIDE™ 71 中間導管，專為急性缺血性中風患者的血管重建而設計。這款新一代導管屬於 CEREGLIDE 系列，經過優化，可直接將支架回收器（例如 EMBOTRAP™ III 血管重建裝置）吸入並輸送至神經血管系統。

血栓管理設備市場報告重點

  • 目前血栓管理設備市場規模分析（2024 年）及 8 年市場預測（2025-2032 年）
  • 過去三年主要產品/技術發展、併購、合作及合資企業
  • 主導血栓管理設備市場的主要公司
  • 血栓管理設備市場中競爭對手面臨的各種機會
  • 2024 年的主要細分市場及其 2032 年的表現
  • 目前血栓管理設備市場中表現最佳的地區和國家
  • 企業應重點關注的血栓管理設備市場成長機會的地區和國家

經常血栓管理設備市場常見問題

1. 血栓管理設備

  • 血栓管理設備是用於清除週邊血管和神經血管中血栓的醫療器械。

2. 血栓管理設備市場

  • 預計2024年血栓管理設備市場規模將達到18.3879億美元，2025年至2032年的複合年增長率為4.63%，到2032年將達到26.3273億美元。

3.血栓管理設備市場的驅動因素

  • 心血管疾病、糖尿病和高血壓等生活方式相關疾病的盛行率不斷上升，以及持續的產品創新，正在推動血栓管理設備市場的成長。心血管疾病及其相關風險正在推動對先進血栓預防和治療技術的需求。此外，微創高效設備（例如機械血栓切除工具和導管系統）的新發展正在推動市場發展，並使醫護人員更輕鬆地進行血栓管理。預計這些綜合因素將在2025年至2032年的預測期內推動整個血栓管理設備市場的成長。

    4.血栓管理設備市場的主要參與者

    • 血栓管理設備市場的主要參與者包括：愛德華生命科學公司 (Edward LifeSciences Corporation)、史賽克 (Stryker)、醫療器材業務服務公司 (Medical Device Business Services, Inc.)、美敦力公司 (Medtronic PLC)、Penumbra、Microvention 公司、泰爾茂公司 (Terumo Corporation Corporation、波士頓科學公司 (Boston)、Vston Perf）、Pflowas） Ltd.、荷蘭皇家飛利浦公司 (Koninklijke Philips N.V.)、phenox GmbH、AngioDynamics、ARGON MEDICAL、BD、B. Braun Melsungen AG、康德樂 (Cardinal Health)、Braille Biomedica 和庫克 (Cook)。

    5.血栓管理設備市場最大佔有率地區

    • 預計到2024年，北美將在所有地區中佔據血栓管理設備市場的最大佔有率。由於一些關鍵成長因素的重要性，北美血栓管理設備市場預計將在預測期內實現正增長，這些因素包括肥胖、高血壓和糖尿病患病率的上升，深部靜脈血栓 (DVT) 和栓塞患病率的上升，人口老齡化，癌症患病率的上升，以及政府在疾病治療意識方面的舉措不斷增多。

    目錄

    第1章 血栓管理設備市場報告的簡介

    第2章 血栓管理設備市場摘要整理

    第3章 競爭情形

    第4章 法規分析

    • 美國
    • 歐洲
    • 日本
    • 中國

    第5章 血栓管理設備市場主要原因分析

    • 血栓管理設備推動市場要素
      • 心血管疾病盛行率上升
      • 糖尿病和高血壓等生活型態相關疾病發生率上升
      • 產品開發活動增加全球
    • 血栓管理設備市場限制與課題
      • 產品召回數量不斷增加
      • 設備相關併發症風險
    • 血栓管理設備市場機遇
      • 人工智慧整合

    第6章 血栓管理設備市場:波特的五力分析

    第7章 血栓管理設備市場評估

    • 各產品類型
      • 血栓清除裝置
      • 栓塞解剖導管
      • 下腔靜脈濾器
      • 壓縮服裝類
      • 其他
    • 各終端用戶
      • 醫院
      • 門診病人手術中心
      • 居家照護
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 其他地區

    第8章 血栓管理設備市場企業與產品簡介

    • Edward LifeSciences Corporation
    • Stryker
    • Medical Device Business Services, Inc.
    • Medtronic PLC
    • Penumbra
    • Microvention Inc.
    • Terumo Corporation
    • Boston Scientific Inc.
    • Abbott
    • Acandis GmbH
    • Perflow Medical Ltd.
    • Koninklijke Philips N.V.
    • phenox GmbH
    • AngioDynamics
    • ARGON MEDICAL
    • BD
    • B. Braun Melsungen AG
    • Cardinal Health
    • Braile Biomedica Cook

    第9章 KOL的見解

    第10章 計劃方法

    第11章 關於DelveInsight

    第12章 免責聲明和諮詢方式

Product Code: DIMDCL0312

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising prevalence of cardiovascular diseases, increasing prevalence of lifestyle disorders such as diabetes and hypertension, and increased in product developmental activities across the globe.

The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032. The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

Clot Management Devices Market Dynamics:

According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases. Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, affected an estimated 200 million people globally in which approximately 110 million men and 80 million women were affected. Additionally, around 56 million women and 45 million men were stroke survivors. It was estimated that at least 13 million people worldwide lived with congenital heart disease, with potentially millions more undiagnosed.

The rising incidence of cardiovascular diseases (CVDs), such as heart attacks, strokes, and peripheral artery disease, significantly boosts the market for clot management devices. These conditions are often associated with the formation of blood clots, which can lead to life-threatening complications if not treated promptly. Clot management devices, including mechanical thrombectomy systems and catheter-directed thrombolysis, provide minimally invasive options for removing or dissolving clots, improving patient outcomes and reducing the need for complex surgeries thereby escalating the market growth across the globe.

Additionally, according to the recent update provided by the International Diabetes Federation, in 2021, approximately 537 million adults aged 20-79 were living with diabetes. This number was projected to rise to 643 million by 2030 and 783 million by 2045.

Additionally, as per the recent data provided by the IDF Diabetes Atlas, in 2022, out of the 8.75 million people living with type 1 diabetes worldwide, 1.52 million were under 20 years old. Additionally, 62% of all new type 1 diabetes cases in 2022 occurred in people aged 20 years or older. The increasing prevalence of diabetes is driving the demand for clot management devices, as diabetes significantly raises the risk of vascular complications, including blood clot formation. This elevated risk necessitates advanced clot management solutions such as thrombectomy devices, catheter-directed thrombolysis, and other minimally invasive procedures designed to quickly dissolve or remove clots, improving blood flow and reducing complications and thereby boosting the overall market of clot management devices across the globe.

Additionally, companies are amplifying their production of clot management devices and gaining approvals for the new products, thereby strategically expanding their market presence and driving further growth. For instance, in March 2025, Imperative Care, Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the 82cm version of its SymphonyTM 16F Catheter, the company's latest innovation designed to elevate care for patients with venous thrombosis, a serious condition caused by a blood clot forming in the veins of the legs or abdomen that can have a life-threatening impact if left untreated.

However, the increased number of product recalls and the risk of complications associated with clot management devices such as bleeding, vessel damage, or infection may hinder the future market of clot management devices.

Clot Management Devices Market Segment Analysis:

Clot Management Devices by Product Type (Thrombectomy Devices [Catheter-Directed Thrombolysis Devices, Aspiration Devices, and Stent Retrievers], Embelecotomy Catheters, Inferior Vena Cava Filters [Retrievable and Permanent], Compression Garments, and Others), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the clot management market, the stent retrievers category is expected to hold the largest share in the year 2024. This can be ascribed to their advantages such as mechanical thrombectomy with stent retrievers is reported to produce superior clinical outcomes in acute stroke patients compared to medical therapy alone. In addition to that, stent retrievers have a safety profile similar to that of systemic thrombolytic therapy. These devices are designed to mechanically remove blood clots from blocked arteries in the brain, thereby restoring blood flow quickly and effectively often within the critical window for preventing long-term neurological damage.

Moreover, improvements in product design such as the incorporation of platinum for improved visibility (Trevo Provue and Solitaire Platinum) and longer lengths up to 40 mm have helped in improving the first-pass reperfusion outcomes. The entry of recoverable self-expanding thrombectomy devices further offers advantages such as the devices restore flow immediately and avoid the placement of a permanent stent, immediate restoration of blood, and eliminating the need for the placement of a permanent stent thereby reducing the chances of in-stent restenosis. Stent retrievers offer superior outcomes compared to traditional thrombolytic drug therapy alone, including higher rates of recanalization, improved functional recovery, and reduced mortality. This has led to their inclusion in major stroke treatment guidelines and accelerated adoption across hospitals and stroke centers globally. Furthermore, technological innovations such as next-generation stent retrievers with enhanced radial force, better clot integration, and improved navigability are further expanding their clinical utility.

In addition, new product launches are also likely to upsurge the global stent retrievers market during the forecasted period. For instance, in August 2024, Gravity Medical Technology announced the launch of its next-generation stroke treatment devices the Neutron aspiration catheter and the Supernova stent retriever. The Supernova stent retriever's innovative design enhances the capture and removal of hard fibrin-rich (white) clots, which tend to present more in non-Caucasian populations.

Therefore, owing to the above-mentioned factors, the stent retriever's category is expected to generate considerable revenue thereby pushing the overall growth of the global clot management devices market during the forecast period.

North America is expected to dominate the overall clot management devices market:

North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

According, to recent data from the Centers for Disease Control and Prevention (2024), in 2022, approximately 4.9% of adults were diagnosed with coronary heart disease. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.

The rising prevalence of coronary heart disease (CHD) significantly boosts the market for clot management devices. As CHD often leads to the formation of blood clots in coronary arteries, there is an increased demand for effective treatments to restore blood flow and prevent heart attacks. Clot management devices, such as thrombectomy and embolization systems, are essential in managing these conditions, driving their adoption in hospitals and emergency care settings.

Additionally, according to the latest report provided by the Centre for Disease Control and Prevention (2024), estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, had diabetes. Additionally, approximately, 38.1 million individuals aged 18 years and older, representing 14.7% of all U.S. adults, were affected by diabetes. Diabetes often leads to complications such as peripheral artery disease and deep vein thrombosis, where blood clots can block vessels and impair circulation. This rising need for effective clot prevention and treatment in diabetic populations is boosting the adoption of clot management devices, including thrombectomy and catheter systems, in both hospital and outpatient settings thereby escalating the overall market across the region.

Furthermore, one of the key reasons positively influencing the growth of the United States clot management devices market is the rising prevalence of cancers in the US population. As per the latest data provided by GLOBOCAN, in 2022, the estimated new cases of cancer in North America was 2.67 million and the projections were subjected to an increase of 3.83 million by 2045. Cancer patients are thought to have specific abnormal coagulation factors which increase the chances of thrombus formation. Additionally, chemotherapy is also related to the increased risk of venous thrombosis resulting in deep vein thrombosis. Therefore, the rising prevalence of cancers in the country is expected to aid in the growing need for thrombus management devices thereby resulting in an increase in product demand and aiding in the growth of the North America clot management devices market.

In addition, the increased strategic activities by the key market players are also likely to upsurge the clot management devices market across the region during the forecasted period. For instance, in June 2023, Penumbra, Inc., a global healthcare company, received FDA clearance and launched Lightning Bolt(TM) 7, an advanced arterial thrombectomy system. The device introduced modulated aspiration by combining Lightning Intelligent Aspiration technology with a microprocessor algorithm. It was designed to quickly remove large, fibrous arterial clots with minimal blood loss, targeting conditions like acute limb ischemia (ALI), hibernating thrombus, and visceral occlusions.

Therefore, the above-mentioned factors are expected to bolster the growth of the clot management devices market in North America during the forecast period.

Clot Management Devices Market Key Players:

Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

Recent Developmental Activities in the Clot Management Devices Market:

  • In April 2024, Penumbra Inc. launched Lightning Flash 2.0 - the latest CAVT technology designed to rapidly remove blood clots
  • In February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, announced the launch of the CEREGLIDE(TM) 71 Intermediate Catheter, designed for revascularization in acute ischemic stroke patients. This next-generation catheter, part of the CEREGLIDE family, was optimized for direct aspiration and delivering stent retrievers like the EMBOTRAP(TM) III Revascularization Device into the neurovasculature.

Key takeaways from the clot management devices market report study:

  • Market size analysis for current clot management devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the clot management devices market.
  • Various opportunities available for the other competitors in the clot management devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current clot management devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for clot management devices market growth in the coming future?

Target audience who can benefit from this clot management devices market report study:

  • Clot management devices product providers
  • Research organizations and consulting companies
  • Clot management devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in clot management devices
  • Various end-users who want to know more about the clot management devices market and the latest technological developments in the clot management devices market.

Frequently Asked Questions for the Clot Management Devices Market:

1. What are clot management devices?

  • Clot management devices are medical devices that are employed in the removal of blood clots from peripheral as well as neurovasculature.

2. What is the market for clot management devices?

  • The clot management devices market was valued at USD 1,838.79 million in 2024, growing at a CAGR of 4.63% during the forecast period from 2025 to 2032 to reach USD 2,632.73 million by 2032.

3. What are the drivers for the clot management devices market?

  • The rising prevalence of cardiovascular diseases, lifestyle disorders like diabetes and hypertension, and ongoing product innovation are driving the growth of the clot management devices market. Cardiovascular conditions and related risks from these disorders increase demand for advanced clot prevention and treatment technologies. Additionally, new developments in less invasive and more effective devices, such as mechanical thrombectomy tools and catheter-based systems, are boosting market expansion, making it easier for healthcare providers to manage blood clots. Together, these factors are expected to boost the overall market for clot management devices during the forecast period from 2025 to 2032.

4. Who are the key players operating in the clot management devices market?

  • Some of the key market players operating in the clot management devices market include Edward LifeSciences Corporation, Stryker, Medical Device Business Services, Inc., Medtronic PLC, Penumbra, Microvention Inc., Terumo Corporation, Boston Scientific Inc, Abbott, Acandis GmbH, Perflow Medical Ltd., Koninklijke Philips N.V., phenox GmbH, AngioDynamics, ARGON MEDICAL, BD, B. Braun Melsungen AG, Cardinal Health., Braile Biomedica, Cook, and others.

5. Which region has the highest share in the clot management devices market?

  • North America is expected to account for the highest proportion of the clot management devices market in 2024, out of all regions. Owing to the significance of key growth factors such as the rising prevalence of DVT, embolism due to the increasing prevalence of obesity, hypertension, and diabetes, the aging population, the growing prevalence of cancers, and rising government initiatives regarding disease treatment awareness, the North America clot management devices market is expected to witness positive growth during the forecast period.

Table of Contents

1. Clot Management Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Clot Management Devices Market Executive Summary

  • 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1 The United States
  • 4.2 Europe
  • 4.3 Japan
  • 4.4 China

5. Clot Management Devices Market Key Factors Analysis

  • 5.1. Clot Management Devices Market Drivers
    • 5.1.1 The rising prevalence of cardiovascular diseases
    • 5.1.2 Increasing prevalence of lifestyle disorders such as diabetes and hypertension
    • 5.1.3 Increased product developmental activities across the globe.
  • 5.2 Clot Management Devices Market Restraints and Challenges
    • 5.2.1 Increased number of product recalls
    • 5.2.2 The risk of complications associated with the devices
  • 5.3 Clot Management Devices Market Opportunities
    • 5.3.1 Integration of artificial intelligence

6. Clot Management Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Clot Management Devices Market Assessment

  • 7.1 By Product Type
    • 7.1.1 Thrombectomy Devices
      • 7.1.1.1 Catheter-Directed Thrombolysis Devices
      • 7.1.1.2 Aspiration Devices
      • 7.1.1.3 Stent Retrievers
    • 7.1.2 Embelecotomy Catheters
    • 7.1.3 Inferior Vena Cava Filters
      • 7.1.3.1 Retrievable
      • 7.1.3.2 Permanent
    • 7.1.4 Compression Garments
    • 7.1.5 Others
  • 7.2 By End-Users
    • 7.2.1 Hospitals
    • 7.2.2 Ambulatory Surgical Centers
    • 7.2.3 Homecare Settings
    • 7.2.4 Others
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.1.2 Canada Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.1.3 Mexico Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.2 Europe
      • 7.3.2.1 France Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.2.2 Germany Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.2.3 United Kingdom Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.2.4 Italy Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.2.5 Spain Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.2.6 Rest of Europe Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.3.2 Japan Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.3.3 India Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.3.4 Australia Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.3.5 South Korea Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.3.6 Rest of Asia-Pacific Clot Management Devices Market Size in USD million (2022-2032)
    • 7.3.4 Rest of the World (RoW)
      • 7.3.4.1 Middle East Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.4.2 Africa Clot Management Devices Market Size in USD million (2022-2032)
      • 7.3.4.3 South America Clot Management Devices Market Size in USD million (2022-2032)

8. Clot Management Devices Market Company and Product Profiles

  • 8.1 Edward LifeSciences Corporation
    • 8.1.1 Company Overview
    • 8.1.2 Company Snapshot
    • 8.1.3 Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5 Entropy
  • 8.2 Stryker
    • 8.2.1 Company Overview
    • 8.2.2 Company Snapshot
    • 8.2.3 Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5 Entropy
  • 8.3 Medical Device Business Services, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Company Snapshot
    • 8.3.3 Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5 Entropy
  • 8.4 Medtronic PLC
    • 8.4.1 Company Overview
    • 8.4.2 Company Snapshot
    • 8.4.3 Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5 Entropy
  • 8.5 Penumbra
    • 8.5.1 Company Overview
    • 8.5.2 Company Snapshot
    • 8.5.3 Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5 Entropy
  • 8.6 Microvention Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Company Snapshot
    • 8.6.3 Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5 Entropy
  • 8.7 Terumo Corporation
    • 8.7.1 Company Overview
    • 8.7.2 Company Snapshot
    • 8.7.3 Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5 Entropy
  • 8.8 Boston Scientific Inc.
    • 8.8.1 Company Overview
    • 8.8.2 Company Snapshot
    • 8.8.3 Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5 Entropy
  • 8.9 Abbott
    • 8.9.1 Company Overview
    • 8.9.2 Company Snapshot
    • 8.9.3 Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5 Entropy
  • 8.10. Acandis GmbH
    • 8.10.1 Company Overview
    • 8.10.2 Company Snapshot
    • 8.10.3 Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5 Entropy
  • 8.11. Perflow Medical Ltd.
    • 8.11.1 Company Overview
    • 8.11.2 Company Snapshot
    • 8.11.3 Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5 Entropy
  • 8.12. Koninklijke Philips N.V.
    • 8.12.1 Company Overview
    • 8.12.2 Company Snapshot
    • 8.12.3 Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5 Entropy
  • 8.13. phenox GmbH
    • 8.13.1 Company Overview
    • 8.13.2 Company Snapshot
    • 8.13.3 Financial Overview
    • 8.13.4 Product Listing
    • 8.13.5 Entropy
  • 8.14. AngioDynamics
    • 8.14.1 Company Overview
    • 8.14.2 Company Snapshot
    • 8.14.3 Financial Overview
    • 8.14.4 Product Listing
    • 8.14.5 Entropy
  • 8.15. ARGON MEDICAL
    • 8.15.1 Company Overview
    • 8.15.2 Company Snapshot
    • 8.15.3 Financial Overview
    • 8.15.4 Product Listing
    • 8.15.5 Entropy
  • 8.16. BD
    • 8.16.1 Company Overview
    • 8.16.2 Company Snapshot
    • 8.16.3 Financial Overview
    • 8.16.4 Product Listing
    • 8.16.5 Entropy
  • 8.17. B. Braun Melsungen AG
    • 8.17.1 Company Overview
    • 8.17.2 Company Snapshot
    • 8.17.3 Financial Overview
    • 8.17.4 Product Listing
    • 8.17.5 Entropy
  • 8.18. Cardinal Health
    • 8.18.1 Company Overview
    • 8.18.2 Company Snapshot
    • 8.18.3 Financial Overview
    • 8.18.4 Product Listing
    • 8.18.5 Entropy
  • 8.19. Braile Biomedica
    • 8.19.1 Company Overview
    • 8.19.2 Company Snapshot
    • 8.19.3 Financial Overview
    • 8.19.4 Product Listing
    • 8.19.5 Entropy
  • 8.20. Cook
    • 8.20.1 Company Overview
    • 8.20.2 Company Snapshot
    • 8.20.3 Financial Overview
    • 8.20.4 Product Listing
    • 8.20.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Clot Management Devices Market in Global (2022-2032)
  • Table 3: Clot Management Devices Market in Global by Product Type (2022-2032)
  • Table 4: Clot Management Devices Market in Global by End-User (2022-2032)
  • Table 5: Clot Management Devices Market in Global by Geography (2022-2032)
  • Table 6: Clot Management Devices Market in North America (2022-2032)
  • Table 7: Clot Management Devices Market in the United States (2022-2032)
  • Table 8: Clot Management Devices Market in Canada (2022-2032)
  • Table 9: Clot Management Devices Market in Mexico (2022-2032)
  • Table 10: Clot Management Devices Market in Europe (2022-2032)
  • Table 11: Clot Management Devices Market in France (2022-2032)
  • Table 12: Clot Management Devices Market in Germany (2022-2032)
  • Table 13: Clot Management Devices Market in United Kingdom (2022-2032)
  • Table 14: Clot Management Devices Market in Italy (2022-2032)
  • Table 15: Clot Management Devices Market in Spain (2022-2032)
  • Table 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Clot Management Devices Market in China (2022-2032)
  • Table 19: Clot Management Devices Market in Japan (2022-2032)
  • Table 20: Clot Management Devices Market in India (2022-2032)
  • Table 21: Clot Management Devices Market in Australia (2022-2032)
  • Table 22: Clot Management Devices Market in South Korea (2022-2032)
  • Table 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Clot Management Devices Market in the Rest of the World (2022-2032)
  • Table 25: Clot Management Devices Market in the Middle East (2022-2032)
  • Table 26: Clot Management Devices Market in Africa (2022-2032)
  • Table 27: Clot Management Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Clot Management Devices Market in Global (2022-2032)
  • Figure 3: Clot Management Devices Market in Global by Product Type (2022-2032)
  • Figure 4: Clot Management Devices Market in Global by End-User (2022-2032)
  • Figure 5: Clot Management Devices Market in Global by Geography (2022-2032)
  • Figure 6: Clot Management Devices Market in North America (2022-2032)
  • Figure 7: Clot Management Devices Market in the United States (2022-2032)
  • Figure 8: Clot Management Devices Market in Canada (2022-2032)
  • Figure 9: Clot Management Devices Market in Mexico (2022-2032)
  • Figure 10: Clot Management Devices Market in Europe (2022-2032)
  • Figure 11: Clot Management Devices Market in France (2022-2032)
  • Figure 12: Clot Management Devices Market in Germany (2022-2032)
  • Figure 13: Clot Management Devices Market in United Kingdom (2022-2032)
  • Figure 14: Clot Management Devices Market in Italy (2022-2032)
  • Figure 15: Clot Management Devices Market in Spain (2022-2032)
  • Figure 16: Clot Management Devices Market in the Rest of Europe (2022-2032)
  • Figure 17: Clot Management Devices Market in Asia-Pacific (2022-2032)
  • Figure 18: Clot Management Devices Market in China (2022-2032)
  • Figure 19: Clot Management Devices Market in Japan (2022-2032)
  • Figure 20: Clot Management Devices Market in India (2022-2032)
  • Figure 21: Clot Management Devices Market in Australia (2022-2032)
  • Figure 22: Clot Management Devices Market in South Korea (2022-2032)
  • Figure 23: Clot Management Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 24: Clot Management Devices Market in the Rest of the World (2022-2032)
  • Figure 25: Clot Management Devices Market in the Middle East (2022-2032)
  • Figure 26: Clot Management Devices Market in Africa (2022-2032)
  • Figure 27: Clot Management Devices Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Market Opportunities
  • Figure 31: PORTER'S Five Force Analysis